Alnylam Pharmaceuticals, Inc.

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

TG Therapeutics shares have gained 15.1% since its last earnings report in early September 2026. While the company beat revenue expectations with $240.3M (up 70.3% YoY) driven by strong Briumvi sales, it missed EPS estimates at $0.05 vs. $0.41 expected. The company raised its 2026 revenue guidance to ~$950M. However, analyst estimates have trended downward since the report, and the stock received a Zacks Rank #3 (Hold) with poor Growth and Momentum scores, suggesting limited upside ahead.